iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Update

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 33,149 shares, a growth of 277.5% from the January 29th total of 8,781 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 48,195 shares, the days-to-cover ratio is presently 0.7 days. Based on an average trading volume of 48,195 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.7% of the shares of the company are short sold.

iShares Genomics Immunology and Healthcare ETF Stock Performance

Shares of iShares Genomics Immunology and Healthcare ETF stock traded down $0.62 during trading on Thursday, hitting $30.47. 11,013 shares of the company’s stock were exchanged, compared to its average volume of 43,527. The stock has a market capitalization of $152.35 million, a price-to-earnings ratio of 14.76 and a beta of 1.07. The business has a 50-day simple moving average of $28.31 and a 200-day simple moving average of $25.79. iShares Genomics Immunology and Healthcare ETF has a 52-week low of $17.26 and a 52-week high of $31.39.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

Several large investors have recently made changes to their positions in the company. Portland Global Advisors LLC purchased a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 2nd quarter worth about $2,099,000. Flow Traders U.S. LLC acquired a new position in iShares Genomics Immunology and Healthcare ETF in the 2nd quarter worth about $931,000. Ameriprise Financial Inc. boosted its position in iShares Genomics Immunology and Healthcare ETF by 8.4% during the third quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock worth $1,688,000 after purchasing an additional 5,540 shares in the last quarter. Finally, Triumph Capital Management acquired a new stake in iShares Genomics Immunology and Healthcare ETF in the third quarter valued at approximately $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.